IDG Capital

IDG Capital is a Beijing-based venture and growth-stage investment firm that backs technology-enabled companies across global markets, with a strong emphasis on China and Asia. It invests across seed, early, later, and growth stages and pursues buyouts, with interests spanning information technology, software, consumer products and services, healthcare, energy, SaaS, mobile, TMT, and advanced manufacturing. The firm leverages a worldwide network of limited partners, including sovereign wealth funds, pension funds, institutional investors, and philanthropic and educational endowments, to support portfolio companies. With deep local market knowledge and extensive relationships with business leaders, IDG Capital combines global perspective with local execution to facilitate inbound and outbound opportunities in China and the broader Asian region.

Xiaohui Cao

Partner

Guangfu Cui

Partner

Jun Fang

Partner

Mei Gao

Partner

Young Guo

General Partner

Ning Kang

Managing Director

Jianguang Li

Venture Partner

Meng Lian

Vice President of Investment

Dongliang Lin

Partner

Yikun Liu

Partner

Michelle Ma

Partner

Patrick McGovern

Founder and Chairman

Kuiguang Niu

Partner

Hugo Shong

Co-Chairman

Chen Tong

Partner

Jeacy Yan

Partner

Fei Yang

Director of IPO Division

Jin Yu Ph.D

Partner

Jianbin Zhang

Venture Partner

Maria Zhang

Venture Partner

Haitao Zhang

Managing Director

Zhiyong Zhen

Principal

Past deals in Medical Devices

Wanhai Medical

Series A in 2025
Wanhai Medical is a prominent manufacturer specializing in the development and production of self-medication injection systems.

Haimai Medical

Series A in 2024
Haimai Medical is a platform for tissue engineering and regenerative medicine technology. It focused on the development and manufacture of allogeneic small-caliber tissue-engineered blood vessels suitable for the establishment of chronic renal failure dialysis vascular access, lower extremity arterial trauma blood vessel replacement, lower extremity atherosclerosis, and coronary heart disease bypass surgery.

Luxet

Series A in 2024
Luxet specializes in the development of advanced nano-optical detection technology tailored for a variety of sectors, including industry, scientific research, and medical applications. The company designs high-end detection instruments specifically for microscopes, enabling users to achieve precise detection and analysis. By focusing on cutting-edge technology, Luxet aims to enhance the capabilities of professionals across multiple fields, providing tools that facilitate advanced research and innovation.

Yuewei Medical

Series A in 2023
Yuewei Medical is a developer of interventional medical devices specifically designed for cardiac surgery. The company focuses on creating innovative solutions that enhance the entire process of medical device development and implementation in this field. Its product portfolio includes devices such as coronary artery bypass graft fixators, intraoperative ultrasonic flow detectors, left ventricular assist devices, and coronary anastomosis auxiliary systems. By providing advanced medical devices, Yuewei Medical aims to contribute significantly to the advancement of cardiac surgery and improve patient outcomes.

Cosminde

Series A in 2023
Cosminde is an endoscope manufacturer with a solid capacity base that integrates research, development, and manufacturing. Medical endoscopes and veterinary endoscopes are both included in the category of endoscope products. The most prevalent of these are digestive endoscopes, including upper and lower gastrointestinal electronic endoscopes, medical endoscope image processors, medical cold light sources, and their auxiliary peripheral products, which are used in endoscope centers, the Department of Gastroenterology, and other departments.

Biotyx Medical

Series B in 2023
Biotyx Medical specializes in the development and sale of innovative medical devices focused on cardiovascular health. The company manufactures biodegradable vascular materials and stents made from iron, which are designed to be bioabsorbable. These products aim to provide doctors with safe and effective treatment options for patients at affordable prices.

Xinhengrui Medical

Series A in 2023
Xinhengrui Medical provides heart-assisted medical devices and offers complete, safe, and effective intelligent mechanical-assisted therapy solutions for heart failure patients.

Taichu Biotechnology

Series A in 2023
Taichu Biotechnology is a biopharmaceutical company that specializes in providing customized Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services. The company operates across the entire industry chain, focusing on drug non-clinical research and development, as well as the production of novel pharmaceuticals. Taichu's offerings encompass non-clinical drugability evaluations, antibody drug development, and the research and development of chemical preparations. By delivering tailored technical services for both individual and combined business sectors, Taichu Biotechnology supports the research and development, as well as the manufacturing processes, involved in creating a variety of new drugs.

Yuewei Medical

Seed Round in 2023
Yuewei Medical is a developer of interventional medical devices specifically designed for cardiac surgery. The company focuses on creating innovative solutions that enhance the entire process of medical device development and implementation in this field. Its product portfolio includes devices such as coronary artery bypass graft fixators, intraoperative ultrasonic flow detectors, left ventricular assist devices, and coronary anastomosis auxiliary systems. By providing advanced medical devices, Yuewei Medical aims to contribute significantly to the advancement of cardiac surgery and improve patient outcomes.

Kelun Biotech

Series B in 2022
Kelun Biotech is a biopharmaceutical company dedicated to researching, developing, manufacturing, and commercializing innovative drugs. With over a decade of experience, they specialize in antibody-drug conjugates (ADCs) to address prevalent or hard-to-treat cancers and other diseases worldwide.

Huihe Healthcare

Series C in 2022
Huihe Healthcare, founded in 2019 and based in Shanghai, China, focuses on the development and research of medical devices for structural heart diseases. The company is dedicated to creating innovative intervention devices, including systems for tricuspid valve repair, aimed at offering effective solutions for patients suffering from various heart conditions. Through its commitment to research and development, Huihe Healthcare strives to advance medical technology in the field of cardiology.

Asia Pacific Medical Group

Series A in 2022
Asia Pacific Medical Group operates a network of hospitals designed to cater to both local and international patients across Southeast Asia. The organization provides a comprehensive range of medical services, including neurology, oncology, cardiovascular medicine, pediatrics, and dermatology. Their facilities are equipped to deliver advanced treatments such as gamma knife therapy, neurosurgery, and plastic surgery, among others. By focusing on affordability, Asia Pacific Medical Group aims to make high-quality healthcare accessible, allowing patients to receive effective treatment for various medical conditions in a supportive environment.

Layerwave Bio

Series A in 2022
Layerwave Bio is a developer of IVD diagnostic instrument reagents and biomedical scientific research instruments.

X-MAGTECH

Series A in 2022
X-MAGTECH is a technology platform for measuring extremely weak magnetic fields.

SUSTAO

Series A in 2022
SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots.

Puyi Biotechnology

Seed Round in 2022
Puyi Biotechnology is a company focused on the high-value medical device market, with a specialization in material science and drug delivery technology. It has established a distinctive presence in several medical fields, including ear, nose, and throat (ENT) care, reproductive health, and medical aesthetics. The company develops minimally-invasive implanted medical devices designed for healthcare professionals, particularly emphasizing degradable, drug-releasing sinus stents that enhance patient outcomes following surgery. Through its innovative approach, Puyi Biotechnology aims to improve treatment efficacy and patient recovery in various medical applications.

Guoyi Quantum

Series C in 2021
Guoyi Quantum is a company that uses quantum precision measurement as its core technology to provide enterprises, governments, and research institutions around the world with core key devices represented by enhanced quantum sensors, scientific instruments and equipment for analysis and testing, and enable industry applications. Products and services such as core technology solutions. The company faces the fields of advanced materials, semiconductors, quantum science, life technology, medicine and clinical research, and is committed to helping customers promote the development of technology more efficiently and explore the future of mankind.

ColorTech Bio

Series B in 2021
ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Tripod Preclinical Research

Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Guangzhou Creative Biosciences

Series D in 2021
Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

X-MAGTECH

Seed Round in 2021
X-MAGTECH is a technology platform for measuring extremely weak magnetic fields.

ColorTech Bio

Series A in 2021
ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Huihe Healthcare

Series B in 2021
Huihe Healthcare, founded in 2019 and based in Shanghai, China, focuses on the development and research of medical devices for structural heart diseases. The company is dedicated to creating innovative intervention devices, including systems for tricuspid valve repair, aimed at offering effective solutions for patients suffering from various heart conditions. Through its commitment to research and development, Huihe Healthcare strives to advance medical technology in the field of cardiology.

Huihe Medical

Series B in 2021
medical

ColorTech Bio

Series A in 2021
ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Kelun Biotech

Funding Round in 2021
Kelun Biotech is a biopharmaceutical company dedicated to researching, developing, manufacturing, and commercializing innovative drugs. With over a decade of experience, they specialize in antibody-drug conjugates (ADCs) to address prevalent or hard-to-treat cancers and other diseases worldwide.

MicroTech Medical

Series D in 2020
MicroTech Medical, founded in January 2011 in Hangzhou Future Technical City, is a company focused on the research, development, and manufacturing of innovative and affordable medical devices for diabetes care. The firm specializes in creating both treatment and monitoring devices aimed at improving diabetes management, primarily serving the Chinese market while also reaching international customers. With significant backing from Eli Lilly and Company, MicroTech Medical is dedicated to enhancing the quality of life for individuals living with diabetes through advanced technology solutions.

NeoCura

Series A in 2020
NeoCura is a biotechnology company based in Shenzhen, China, founded in 2017. It specializes in developing AI-based platforms and diagnostic tests aimed at enhancing cancer therapies. The company's offerings include NeoCura AI ALPINE, a platform for predicting tumor neoantigens, and NeoCura AI EVEREST, which validates these neoantigens to improve patient outcomes. Additionally, NeoCura TP serves as an intelligent companion diagnostic tool that forecasts treatment options for immunotherapy drugs, while NeoCura Ag focuses on patient-specific neoantigen immunotherapy. Alongside these platforms, NeoCura also provides diagnostics and medical laboratory services, leveraging AI to analyze molecular biology and clinical data to assist physicians in refining cancer diagnosis and treatment strategies.

Weimai

Series C in 2020
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.

Guangzhou Creative Biosciences

Series C in 2020
Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

MGI Tech

Series B in 2020
MGI Tech is a company that specializes in the development of sequencing devices and multi-omics platforms, including genetic sequencing, medical imaging, and laboratory automation. By producing high-throughput gene sequencers and associated consumables and reagents, MGI Tech supports advancements in life science research and healthcare. The company aims to provide effective and affordable healthcare solutions, facilitating real-time and comprehensive systems for precision medicine and related fields. Its mission focuses on enhancing life science tools and fostering innovation in digital health, contributing to improved healthcare outcomes.

Fourier Intelligence

Series B in 2019
Fourier Intelligence is a Shanghai-based technology and design company that specializes in the development of exoskeleton robotic products and services aimed at rehabilitation and orthoses. The company offers advanced robotics technology, including upper-limb rehabilitation robotics and lower-limb exoskeletons, which assist individuals with disabilities in overcoming physical limitations, enabling them to stand and walk again. Its innovative products not only enhance the quality of life for users but also improve productivity by reducing fatigue and facilitating the transportation of heavy objects in various sectors. Fourier Intelligence is committed to advancing healthcare and rehabilitation through its pioneering technologies, empowering individuals to regain mobility and independence.

Weimai

Series C in 2019
Weimai is a developer of a health application platform that aims to enhance medical and health services. The platform offers various features, including Internet-based appointment scheduling, maternal and child disease management, grading diagnosis and treatment, remote diagnosis, and medical records management. By cooperating with local hospitals, Weimai provides a range of services such as medical consultations, internet diagnosis and treatment, health management, and on-site medical and nursing assistance. This integration not only facilitates access to medical care for patients but also helps hospitals improve their operational efficiency. Ultimately, Weimai's goal is to deliver a comprehensive family doctor application that brings medical expertise into homes.

Guangzhou Creative Biosciences

Series B in 2019
Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

Yuce Biological Technology

Series B in 2018
Yuce Biological Technology, founded in 2015 and based in Shenzhen, China, specializes in cancer immunotherapy and genetic testing services aimed at enhancing tumor precision immunotherapy. The company offers a range of products, including the YuceOne ICIs test, which supports tumor immunotherapy, and the YuceOne Plus test, designed to detect significant genetic mutations and tumor neonatal antigens to guide therapeutic decisions. Additionally, Yuce provides comprehensive tumor gene detection services that encompass immunotherapy, targeted therapy, chemotherapy, tumor vaccines, and personalized cell therapy. The company also engages in neonatal antigen prediction and tumor mutation load analysis to further support immunotherapy efforts. Its services extend to pharmaceutical offerings, including drug biomarker development and personalized treatment solutions. With a branch located in Shanghai, Yuce Biological Technology is committed to advancing cancer treatment through innovative genetic testing and immunotherapeutic strategies.

XPECT Vision

Series B in 2018
Founded in 2015, Xpect Vision Technology is a high-tech company specializing in the development of innovative imaging technology, particularly photon-counting X-ray imaging. The company manufactures medical imaging chips designed for the medical detection and service industry, utilizing advanced digital X-ray imaging technology and CMOS X-ray detection methods. These imaging chips are integrated into medical electronic products, enabling physicians to enhance the accuracy of cancer diagnoses and improve overall efficiency in medical services. Xpect Vision is positioned to lead future developments in high-speed and high-definition imaging solutions.

Fourier Intelligence

Series A in 2018
Fourier Intelligence is a Shanghai-based technology and design company that specializes in the development of exoskeleton robotic products and services aimed at rehabilitation and orthoses. The company offers advanced robotics technology, including upper-limb rehabilitation robotics and lower-limb exoskeletons, which assist individuals with disabilities in overcoming physical limitations, enabling them to stand and walk again. Its innovative products not only enhance the quality of life for users but also improve productivity by reducing fatigue and facilitating the transportation of heavy objects in various sectors. Fourier Intelligence is committed to advancing healthcare and rehabilitation through its pioneering technologies, empowering individuals to regain mobility and independence.

Ping An Good Doctor

Series F in 2018
Ping An Health Internet is a wholly owned subsidiary of China Ping An Group, an important member of the Internet business segment/. It was established in August 2014 with 350 million yuan registered capital and is headquartered in Shanghai, China. Companies around the network of doctors, drug network and information network formed three product lines, involving online inquiry, a plurality of segments of the doctor-patient health care management, drug O2O, electronic health records, chronic disease management, child health services. Chinese company to the mobile Internet era medical wisdom of the leader as the goal, to create a user-stop health management solutions provider, China's largest Internet to build a healthy industry ecosystem. Ping An Health Internet also developed a children's health management and chronic disease management, and other vertical applications, to meet the needs of market segments. Reform the health care system combined with the trend, the company vigorously promote the integration of physician resources.

WinnTi Medical

Series B in 2017
WinnTi Medical creates medical devices through continuous product innovations and manufacturing improvements, meeting surgeons' increasing demands, and improving patients' wellness.

Qlife Lab

Series A in 2017
Qlife Lab is a developer of precision medicine technology focused on enhancing laboratory diagnosis, particularly for cardiovascular and metabolic disorders. The company offers solutions that encompass mass spectrometry, metagenomic studies, in vitro testing reagents, and third-party diagnostic services. By integrating these advanced technologies, Qlife Lab aims to facilitate targeted therapy and improve health outcomes in the medical and health sectors. Their innovative approach supports medical institutions in delivering accurate inspections and diagnoses, ultimately working to enhance patient health and quality of life.

Qlife Lab

Angel Round in 2017
Qlife Lab is a developer of precision medicine technology focused on enhancing laboratory diagnosis, particularly for cardiovascular and metabolic disorders. The company offers solutions that encompass mass spectrometry, metagenomic studies, in vitro testing reagents, and third-party diagnostic services. By integrating these advanced technologies, Qlife Lab aims to facilitate targeted therapy and improve health outcomes in the medical and health sectors. Their innovative approach supports medical institutions in delivering accurate inspections and diagnoses, ultimately working to enhance patient health and quality of life.

Bondent

Series B in 2017
Bondent Technology Co., Ltd., headquartered in Shanghai, China, specializes in supplying dental equipment and materials. It offers a comprehensive range of services, including technical training, operational and management consulting, decoration design, and financial solutions. Bondent's core business involves the design, development, manufacturing, and sales of oral medical equipment, creating a full ecosystem for the dental and oral health industry.

XPECT Vision

Series A in 2016
Founded in 2015, Xpect Vision Technology is a high-tech company specializing in the development of innovative imaging technology, particularly photon-counting X-ray imaging. The company manufactures medical imaging chips designed for the medical detection and service industry, utilizing advanced digital X-ray imaging technology and CMOS X-ray detection methods. These imaging chips are integrated into medical electronic products, enabling physicians to enhance the accuracy of cancer diagnoses and improve overall efficiency in medical services. Xpect Vision is positioned to lead future developments in high-speed and high-definition imaging solutions.

Ping An Good Doctor

Series A in 2016
Ping An Health Internet is a wholly owned subsidiary of China Ping An Group, an important member of the Internet business segment/. It was established in August 2014 with 350 million yuan registered capital and is headquartered in Shanghai, China. Companies around the network of doctors, drug network and information network formed three product lines, involving online inquiry, a plurality of segments of the doctor-patient health care management, drug O2O, electronic health records, chronic disease management, child health services. Chinese company to the mobile Internet era medical wisdom of the leader as the goal, to create a user-stop health management solutions provider, China's largest Internet to build a healthy industry ecosystem. Ping An Health Internet also developed a children's health management and chronic disease management, and other vertical applications, to meet the needs of market segments. Reform the health care system combined with the trend, the company vigorously promote the integration of physician resources.

Cardea

Angel Round in 2016
Cardea provides energy-based, intelligent, minimally invasive medical equipment for surgery. They produce, research, and develop medical equipment for surgery. They also provide packaging and shipping services.

Fourier Intelligence

Angel Round in 2015
Fourier Intelligence is a Shanghai-based technology and design company that specializes in the development of exoskeleton robotic products and services aimed at rehabilitation and orthoses. The company offers advanced robotics technology, including upper-limb rehabilitation robotics and lower-limb exoskeletons, which assist individuals with disabilities in overcoming physical limitations, enabling them to stand and walk again. Its innovative products not only enhance the quality of life for users but also improve productivity by reducing fatigue and facilitating the transportation of heavy objects in various sectors. Fourier Intelligence is committed to advancing healthcare and rehabilitation through its pioneering technologies, empowering individuals to regain mobility and independence.

Taibang Biological Group

Post in 2015
Taibang Biological Group is a Chinese biopharmaceutical company specializing in the development, manufacture, and sale of plasma-derived products. The company offers a comprehensive range of human plasma-based biopharmaceuticals, including human albumin, human immunoglobulin, and human coagulation factors. Taibang is involved in research and development as well as the production and sales of these blood products and other biological products, catering to the specific needs of its clients. Through its extensive product offerings, Taibang aims to meet the demands of the biopharmaceutical market.

Origene

Venture Round in 2015
OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

WinnTi Medical

Series B in 2015
WinnTi Medical creates medical devices through continuous product innovations and manufacturing improvements, meeting surgeons' increasing demands, and improving patients' wellness.

WinnTi Medical

Series A in 2014
WinnTi Medical creates medical devices through continuous product innovations and manufacturing improvements, meeting surgeons' increasing demands, and improving patients' wellness.

Leo Medical Co.

Series A in 2014
Leo Medical is a high-tech medical company that creates, produces, and sells cutting-edge medical products. Leo Medical develops medical devices that use cutting-edge biomedical technology to aid in the diagnosis, intervention, and treatment of disorders of the digestive and circulatory systems. They feel that a minimally invasive technique is the most humane way to treat patients while without sacrificing the procedure's quality. Minimal invasion in medical treatments frequently allows patients to heal faster and doctors to simplify medical operations. It is a win-win situation for everyone. Leo Medical was founded in 2011 and is headquartered in Jiangsu, P.R. China.

MEC

Series B in 2014
MEC is a developer of a clinical care information system created to allow close monitoring and treatment services, anywhere and whenever needed. It shows a combination and optimization of medical resources, and the management of chronic diseases, and offers comprehensive solutions and technological services. Through the integration of hospital outside the vital signs information, the company's clinical care information system aids the hospital in developing the vital signs of the basic data platform, enabling patients to obtain vital signs data based on the value of health management.

Suzhou BeiAng Technology

Series A in 2013
Suzhou BeiAng Technology Co., Ltd., established in China, is a high-tech enterprise dedicated to the research, development, and sales of air purifiers. Founded by experienced professionals with backgrounds from prestigious U.S. institutions and Silicon Valley entrepreneurship, the company specializes in innovative air filtration technology. It offers a range of air purification devices designed for various small spaces, such as nurseries, offices, and vehicles, capable of removing particles as minute as 20 nanometers, including those from second-hand smoke, thereby enhancing users' respiratory health. The company's technological advancements are protected by numerous international patents.

Origene

Series C in 2013
OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Baihe Medical

Corporate Round in 2013
Baihe Medical is a manufacturer specializing in disposable medical supplies. It focuses on producing items like catheters, hemodialysis products, needles, and feeding tubes used in anesthesia, blood purification, and infusion procedures. The company's mission is to ensure patient safety and comfort by providing high-quality, reliable medical consumables.

Origene

Series B in 2010
OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Kanghui

Series B in 2008
Changzhou Kanghui Medical Innovation Co., Ltd. is a Chinese company specializing in the manufacture and distribution of orthopedic products, including implants, surgical instruments, and devices for trauma, spine, and joint reconstruction. Established in 1997 and headquartered in Changzhou, Jiangsu Province, the company focuses on research and development to provide advanced and cost-effective solutions for orthopedic patients, enhancing their recuperation and quality of life. Kanghui serves both domestic and international OEM orthopedic companies and has expanded its presence with offices in major cities such as Shanghai, Beijing, Guangzhou, and Xi'an. As a wholly foreign-owned enterprise, Kanghui operates under the investment of China Kanghui Holdings.

Andon Health

Series A in 2007
Andon Health Co., Ltd. is a Tianjin-based company that develops, manufactures, and sells a wide range of health electronics and intelligent hardware products. Founded in 1995, the company specializes in medical instruments such as sphygmomanometers, blood glucose meters, thermometers, and fetal heart rate monitors. It also offers devices for managing diabetes, including wrist and arm blood pressure monitors. Additionally, Andon Health provides products aimed at mothers and babies, such as ovulation and pregnancy tests, as well as video monitors. The company serves both OEM and ODM customers globally, positioning itself as a key player in the healthcare product market.

Kanghui

Series A in 2006
Changzhou Kanghui Medical Innovation Co., Ltd. is a Chinese company specializing in the manufacture and distribution of orthopedic products, including implants, surgical instruments, and devices for trauma, spine, and joint reconstruction. Established in 1997 and headquartered in Changzhou, Jiangsu Province, the company focuses on research and development to provide advanced and cost-effective solutions for orthopedic patients, enhancing their recuperation and quality of life. Kanghui serves both domestic and international OEM orthopedic companies and has expanded its presence with offices in major cities such as Shanghai, Beijing, Guangzhou, and Xi'an. As a wholly foreign-owned enterprise, Kanghui operates under the investment of China Kanghui Holdings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.